{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:51:55Z","timestamp":1781801515269,"version":"3.54.5"},"reference-count":47,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This systematic review and meta-analysis investigates the association between statin use and clinical outcomes in non-small cell lung cancer (NSCLC) patients, focusing on the therapeutic potential of statins and their impact on patient prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The review includes a mix of prospective and retrospective cohort studies and randomised controlled trials to assess the relationship between statin use and NSCLC outcomes. ROBINS-I tool was used for assessing risk of bias, ensuring methodological rigour.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>A literature search was conducted across several databases, including MEDLINE (PubMed), EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials. The databases were searched from inception to June 2024.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria<\/jats:title>\n                  <jats:p>Participants included adult NSCLC patients prescribed statins before or after diagnosis, with no restrictions on sex, age or disease stage. Interventions of interest were statin medications, typically used for hypercholesterolemia, and also investigated for anticancer properties. The primary outcome was overall survival (OS), with secondary outcomes including progression-free survival (PFS), cancer-specific survival and NSCLC recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data extraction and synthesis<\/jats:title>\n                  <jats:p>Data extraction was performed independently by two reviewers. Results were synthesised via a random-effects model, with forest plots illustrating HRs for OS and PFS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The meta-analysis included 25 studies with 51 536 NSCLC patients. Statin use was associated with improved OS (HR 0.77, 95% CI 0.70 to 0.85). A trend towards improved PFS was observed but did not reach statistical significance (HR 0.87, 95%\u2009CI 0.71 to 1.07).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Statin use may improve survival outcomes in NSCLC patients. These findings support the potential therapeutic role of statins in NSCLC management and call for further clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42016047524.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-093874","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T09:45:22Z","timestamp":1751708722000},"page":"e093874","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Role of statins in non-small cell lung cancer treatment: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-6590","authenticated-orcid":false,"given":"Guangyu","family":"Liu","sequence":"first","affiliation":[{"name":"Anesthesiology Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"2025080306100829000_15.7.e093874.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025080306100829000_15.7.e093874.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"2025080306100829000_15.7.e093874.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20324"},{"key":"2025080306100829000_15.7.e093874.4","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025080306100829000_15.7.e093874.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1751"},{"key":"2025080306100829000_15.7.e093874.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"2025080306100829000_15.7.e093874.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022161","article-title":"Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol","volume":"8","author":"Li","year":"2018","journal-title":"BMJ Open"},{"key":"2025080306100829000_15.7.e093874.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025080306100829000_15.7.e093874.9","first-page":"137","article-title":"Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study","volume":"10","author":"Omori","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2025080306100829000_15.7.e093874.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025080306100829000_15.7.e093874.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025080306100829000_15.7.e093874.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2025080306100829000_15.7.e093874.13","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/j.prro.2020.12.006","article-title":"Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer","volume":"11","author":"Atkins","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"2025080306100829000_15.7.e093874.14","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz101","article-title":"Reduced Protumorigenic Tumor-Associated Macrophages With Statin Use in Premalignant Human Lung Adenocarcinoma","volume":"4","author":"Al Dujaily","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2025080306100829000_15.7.e093874.15","doi-asserted-by":"crossref","DOI":"10.1378\/chest.2224116","article-title":"Effect of Statins and Metformin on Survival in Patients With Non-small Cell Lung Cancer (NSCLC)","volume":"148","author":"Duma","year":"2015","journal-title":"Chest"},{"key":"2025080306100829000_15.7.e093874.16","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1007\/s13277-015-3249-x","article-title":"Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation","volume":"36","author":"Fiala","year":"2015","journal-title":"Tumour Biol"},{"key":"2025080306100829000_15.7.e093874.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2525"},{"key":"2025080306100829000_15.7.e093874.18","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1200\/jco.2007.25.18_suppl.7638","article-title":"The use of statins may prolong survival of non-small cell lung cancer patients: Final update from 1,205 cases","volume":"25","author":"Hanbali","year":"2007","journal-title":"JCO"},{"key":"2025080306100829000_15.7.e093874.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171137","article-title":"Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study","volume":"12","author":"Hung","year":"2017","journal-title":"PLoS ONE"},{"key":"2025080306100829000_15.7.e093874.20","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.546"},{"key":"2025080306100829000_15.7.e093874.21","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1200\/JCO.2018.36.15_suppl.10045","article-title":"Prognostic benefit of taking statin and\/or metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based epidemiologic study","volume":"36","author":"Lee","year":"2018","journal-title":"JCO"},{"key":"2025080306100829000_15.7.e093874.22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2016.07.006","article-title":"The effect of statins on survival in patients with stage IV lung cancer","volume":"99","author":"Lin","year":"2016","journal-title":"Lung Cancer (Auckl)"},{"key":"2025080306100829000_15.7.e093874.23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e18108","article-title":"Statins (ASIs) may improve the outcome of erlotinib as second line treatment (tx) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC)","volume":"30","author":"Maimon","year":"2012","journal-title":"JCO"},{"key":"2025080306100829000_15.7.e093874.24","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/cas.14493","article-title":"Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan","volume":"111","author":"Nguyen","year":"2020","journal-title":"Cancer Sci"},{"key":"2025080306100829000_15.7.e093874.25","doi-asserted-by":"crossref","unstructured":"Oh TK , Kim K , Jheon S , et al . Impact of Statin Use on Recurrence or Survival After Surgical Curative Resection of Non-Small Cell Lung Cancer. Cancer Control 2018;25. doi:10.1177\/1073274818778000","DOI":"10.1177\/1073274818778000"},{"key":"2025080306100829000_15.7.e093874.26","article-title":"Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC","volume":"2","author":"Patnaik","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2025080306100829000_15.7.e093874.27","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1381729","article-title":"Statin Use Is Associated With Decreased Local Recurrence and Improved Overall Survival in Resectable Non-small Cell Lung Cancer (NSCLC)","volume":"142","author":"Ramakrishna","year":"2012","journal-title":"Chest"},{"key":"2025080306100829000_15.7.e093874.28","article-title":"Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC","volume":"4","author":"Rossi","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"2025080306100829000_15.7.e093874.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71583-w","article-title":"The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer","volume":"10","author":"Su","year":"2020","journal-title":"Sci Rep"},{"key":"2025080306100829000_15.7.e093874.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09385-8","article-title":"A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study","volume":"22","author":"Takada","year":"2022","journal-title":"BMC Cancer"},{"key":"2025080306100829000_15.7.e093874.31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2018.10.022","article-title":"Statins associate with improved mortality among patients with certain histological subtypes of lung cancer","volume":"126","author":"Ung","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"2025080306100829000_15.7.e093874.32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112765","article-title":"Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation","volume":"14","author":"Tsai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025080306100829000_15.7.e093874.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2501","article-title":"1470P Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis","volume":"34","author":"Reuss","year":"2023","journal-title":"Ann Oncol"},{"key":"2025080306100829000_15.7.e093874.34","doi-asserted-by":"crossref","first-page":"109762","DOI":"10.1016\/j.radonc.2023.109762","article-title":"Association between statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: Results from the NI-HEART study","volume":"186","author":"Walls","year":"2023","journal-title":"Radiother Oncol"},{"key":"2025080306100829000_15.7.e093874.35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041277","article-title":"Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy","volume":"15","author":"Zaborowska-Szmit","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025080306100829000_15.7.e093874.36","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.62347\/NZHY5175","article-title":"Statin therapy enhances survival in unresectable stage III lung squamous cell carcinoma with concurrent chemoradiotherapy","volume":"14","author":"Yu","year":"2024","journal-title":"Am J Cancer Res"},{"key":"2025080306100829000_15.7.e093874.37","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions version 6.4 (updated august 2023). Cochrane; 2023. Available: www.training.cochrane.org\/handbook"},{"key":"2025080306100829000_15.7.e093874.38","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2025080306100829000_15.7.e093874.39","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025080306100829000_15.7.e093874.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9450-2"},{"key":"2025080306100829000_15.7.e093874.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2014.02.026"},{"key":"2025080306100829000_15.7.e093874.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2012.01.015"},{"key":"2025080306100829000_15.7.e093874.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.11.003"},{"key":"2025080306100829000_15.7.e093874.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.01.016"},{"key":"2025080306100829000_15.7.e093874.45","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S187690"},{"key":"2025080306100829000_15.7.e093874.46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24536"},{"key":"2025080306100829000_15.7.e093874.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057349","article-title":"Statins and the risk of lung cancer: a meta-analysis","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS ONE"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-093874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T13:10:22Z","timestamp":1754226622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-093874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,5]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-093874"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-093874","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}